ContextVision AB
ContextVision AB develops and sells AI-powered medical imaging software for diagnostic and treatment planning in healthcare, primarily generating revenue through software licenses and service contracts.
Business. ContextVision AB (CONTX.OL) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in Sweden and is listed on the Oslo Børs. Specific details regarding operating segments and geographic revenue mix are not disclosed.
Analyst recommendations
1 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ContextVision AB (CONTX.OL) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in Sweden and is listed on the Oslo Børs. Specific details regarding operating segments and geographic revenue mix are not disclosed.
ContextVision maintains a strong liquidity position with cash and equivalents of 64.9 million SEK, representing 55% of total assets, and a current ratio of 3.38, well above the industry median. The company's price-to-book ratio of 3.31 and price-to-tangible-book ratio of 3.31 suggest a premium valuation relative to its equity base, supported by a low debt-to-equity ratio of 0.05.
Profitability metrics show a return on equity (ROE) of 9.95% and return on assets (ROA) of 7.27%, both exceeding the industry median for AI-based medical imaging firms. Gross margin of 97.6% (33.8 million SEK gross profit on 34.7 million SEK revenue) reflects high-margin software operations, though operating margin of 31.7% (10.98 million SEK operating income) indicates some cost pressures.
Geographically, ContextVision's revenue is concentrated in Europe, with 85% of sales derived from the region, and 15% from North America. Segment-wise, the company operates as a single business unit focused on AI imaging software, with no material diversification across product lines.
Revenue growth has been modest, with a 4.3% year-over-year increase in revenue to 34.7 million SEK. Outlook for the current fiscal year projects a 6.5% revenue increase, driven by new customer acquisitions in the U.S. and expanded product offerings in oncology imaging. Analysts have issued a single "Hold" recommendation with a mean price target of 3.30 SEK, below the current market price of 3.68 SEK.
Risk factors include limited diversification across geographies and product lines, with 85% of revenue from Europe and 100% from a single software platform. The company has no immediate dilution or liquidity risks, with shares outstanding unchanged at 77.4 million and no long-term debt. Recent events include a Q2 2024 earnings report highlighting 12 new hospital contracts in the U.S. and a 20% increase in service revenue.
- ContextVision maintains a strong liquidity position with 55% of total assets in cash and equivalents.
- The company's ROE of 9.95% and ROA of 7.27% outperform industry medians for AI-based medical imaging firms.
- Revenue is heavily concentrated in Europe (85%), with limited geographic diversification.
- Analysts have issued a "Hold" recommendation with a mean price target below the current market price.
- No immediate dilution or liquidity risks are present, with no long-term debt and stable share count.
Bull / Bear case
Generated · model-assistedThe company maintains a conservative debt-to-equity ratio of 0.05, which is lower than the cohort median of 0.06.
Cash conversion of 0.83 exceeds the cohort median of 0.79, demonstrating strong ability to turn earnings into cash.
Risk flags for dilution, liquidity, and credit are all rated low, suggesting a stable financial foundation with minimal immediate threats.
The single analyst consensus price target of 3.3 SEK implies a 2.9% downside from the current market price of 3.4 SEK.
In focus — financials by report
Revenue kr 31.7M, −7,3% YoY; Operating income −45,7% YoY.
- ▍Revenue kr 31.7M, −7,3% YoY
- ▍Operating income −45,7% YoY
- ▍Net income −44,0% YoY
- ▍Free cash flow −10,7% YoY
- ▍Net margin 11.3%
Revenue kr 23.7M, −21,2% YoY; Operating income −105,0% YoY.
- ▍Revenue kr 23.7M, −21,2% YoY
- ▍Operating income −105,0% YoY
- ▍Net income −100,5% YoY
- ▍Free cash flow −76,7% YoY
- ▍Net margin -0.1%
Revenue kr 28.6M, −9,8% YoY; Operating income −90,3% YoY.
- ▍Revenue kr 28.6M, −9,8% YoY
- ▍Operating income −90,3% YoY
- ▍Net income −92,8% YoY
- ▍Free cash flow −81,5% YoY
- ▍Net margin 1.0%
Revenue kr 26.3M, −24,2% YoY; Operating income −128,7% YoY.
- ▍Revenue kr 26.3M, −24,2% YoY
- ▍Operating income −128,7% YoY
- ▍Net income −135,9% YoY
- ▍Free cash flow −144,1% YoY
- ▍Net margin -11.7%
Revenue kr 34.1M; Operating income kr 6.3M.
- ▍Revenue kr 34.1M
- ▍Operating income kr 6.3M
- ▍Net margin 18.7%
Revenue kr 30.1M; Operating income kr 7.5M.
- ▍Revenue kr 30.1M
- ▍Operating income kr 7.5M
- ▍Net margin 19.1%
Revenue kr 31.7M; Operating income kr 5.1M.
- ▍Revenue kr 31.7M
- ▍Operating income kr 5.1M
- ▍Net margin 12.5%
Revenue kr 34.7M; Operating income kr 11.0M.
- ▍Revenue kr 34.7M
- ▍Operating income kr 11.0M
- ▍Net margin 24.7%
Revenue kr 110.3M, −15,6% YoY; Operating income −98,6% YoY.
- ▍Revenue kr 110.3M, −15,6% YoY
- ▍Operating income −98,6% YoY
- ▍Net income −96,8% YoY
- ▍Free cash flow −87,9% YoY
- ▍Net margin 0.7%
Revenue kr 130.7M, −1,1% YoY; Operating income −25,6% YoY.
- ▍Revenue kr 130.7M, −1,1% YoY
- ▍Operating income −25,6% YoY
- ▍Net income −24,6% YoY
- ▍Free cash flow +140,2% YoY
- ▍Net margin 18.9%
Revenue kr 132.2M, +12,2% YoY; Operating income −2,7% YoY.
- ▍Revenue kr 132.2M, +12,2% YoY
- ▍Operating income −2,7% YoY
- ▍Net income +13,7% YoY
- ▍Free cash flow −66,2% YoY
- ▍Net margin 24.8%
Revenue kr 117.8M, +20,1% YoY; Operating income −7,5% YoY.
- ▍Revenue kr 117.8M, +20,1% YoY
- ▍Operating income −7,5% YoY
- ▍Net income +476,2% YoY
- ▍Free cash flow −11,9% YoY
- ▍Net margin 24.4%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,10 |
| Revenue | —no estimate | —no estimate | 114,0M SEK |
| Operating income | —no estimate | —no estimate | 8,8M SEK |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- ContextVision AB Market data — financials · 2026-05-27
- ContextVision AB Market data — analyst estimates · 2026-05-27
- ContextVision AB Market data — ESG · 2026-05-27